Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Attention-Deficit/Hyperactivity Disorder

In brief

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Key facts

Study ID: NCT04781140
Run by: Supernus Pharmaceuticals, Inc.
People needed: 286
Starts: 2024-03-19
Expected to finish: 2026-06-01
Last updated by the study team: 2026-02-18

Who can join

Age: 4 and older, up to 6. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Is male or female 4 years 0 months of age to less than or equal to 5 years 9 months of age at Visit 1 (Screening) and considered medically healthy.
Subject's parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent before completing any study related procedures.
Has a primary diagnosis of ADHD according to DSM-IV-TR criteria and confirmed with the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL).
Has an ADHD-RS-IV-P Total Score of ≥ 28 (males) or ≥ 24 (females) at Visit 1 (Screening) and at Visit 2 (Baseline).
Has a CGI-S score of ≥ 4 (moderate or worse) at Visit 1 (Screening) and at Visit 2 (Baseline).
Has undergone an adequate course of non-pharmacologic treatment or is having symptoms severe enough to warrant pharmacologic treatment without prior non-pharmacologic treatment.
Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school, summer camp or childcare program) at least 2 days a week during study so as to assess symptoms and impairment in a setting outside the home.
Has not initiated any behavioral intervention/therapy within 30 days of Visit 1 (Screening) and does not plan to initiate any new or discontinue any ongoing behavioral intervention/therapy during the study (e.g., subject is eligible if behavioral intervention/therapy is initiated 30 or more days prior to Visit 1 [Screening] and continues with a similar duration/frequency throughout their study).
Subjects who are on ADHD medication at Visit 1 (Screening), but whose ADHD symptoms are not well controlled on current ADHD medication (e.g., meets Inclusion Criterion #4), meet all other inclusion/exclusion criteria, and discontinues ADHD medication at least 7 days prior to the day of Visit 2 (Baseline) are eligible to participate.
Has no current condition in the opinion of the Investigator that could confound efficacy assessments, safety assessments or increase participant risk.
Has lived with the same parent(s) or legal guardian(s) or has lived under a shared living arrangement (e.g., joint legal custody) for greater than or equal to 6 months prior to Visit 1 (Screening).
Has a body weight ≥5th percentile for age and sex at Visit 1 (Screening) and Visit 2 (Baseline).

You may not qualify if…

Has a diagnosis at Screening (per K-SADS-PL) of another psychiatric disorder that is considered to be the primary diagnosis rather than ADHD or has a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator (after consulting medical monitor), will likely interfere with study treatment adherence and/or impact study results.
Has a current diagnosis of a major neurological disorder. The eligibility of those who have seizures, a history of seizure-like events (e.g., syncope, myoclonus, severe muscle spasms), a family history of seizure disorder (immediate family, i.e., sibling, parent), and/or febrile seizures will be assessed on a case-by-case basis after consulting the medical monitor.
History of Bipolar Disorder diagnosed in a first degree relative.
Has global development delay or intellectual disability by medical history.
Has a current diagnosis of a significant (per Investigator's evaluation and/or judgement) systemic disease.
Has body mass index > 95th percentile for the subject's age and sex at Visit 1 (Screening) or Visit 2 (Baseline).
Has a mean resting systolic and diastolic blood pressure* that are both >95th percentile for age sex, and height and has a mean resting pulse rate* that is >95th percentile for age and sex (males: >117 bpm; females: >122 bpm) at Visit 1 (Screening) or Visit 2 (Baseline). * Note: The mean of three measurements while seated.
Has a clinically significant electrocardiogram finding(s) at Visit 1 (Screening).
Is currently taking SPN-812 for ADHD, has previously taken SPN-812 for ADHD, but discontinued due to a lack of efficacy or adverse reactions, or has history of allergic reaction, hypersensitivity or intolerance to viloxazine.
Has an allergy to or cannot swallow pudding and applesauce and cannot swallow intact capsule whole.
Has any food allergy, intolerance, restriction or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in the study.
Has received any investigational drug within the longer of 30 days or 5 half-lives prior to Visit 2 (e.g., first dose of study medication).
Has a positive urine drug test at Visit 1 (Screening). A positive test for amphetamines is allowed for subjects receiving a stimulant ADHD medication at Screening. The subject will be required to discontinue the stimulant for the duration of the study, beginning at least 7 days prior to Visit 2 (Baseline).
Is using of prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) during the Screening Period or (anticipated) for the duration of the study.
Any reason that, in the opinion of the Investigator, would prevent the subject from participating in the study.
Has suicidal ideation ("Yes" indicated on C-SSRS question 4 or 5) or suicidal behavior ("Yes" indicated on C-SSRS for any suicidal behavior) within 6 months prior to or the day of Visit 1 (Screening) or has attempted suicide ("Yes" indicated on C-SSRS for lifetime).

Where it is running

The Center for Clinical Trials, Inc. — Saraland, Alabama, United States (enrolling)
Preferred Research Partners, Inc. — Little Rock, Arkansas, United States (enrolling)
Advanced Research Center (ARC), Inc. — Anaheim, California, United States (enrolling)
Sun Valley Research Center — Imperial, California, United States (enrolling)
Alliance Research — Long Beach, California, United States (enrolling)
IMMUNOe Research Centers — Centennial, Colorado, United States (enrolling)
Luna Research Center — Coral Gables, Florida, United States (enrolling)
Sarkis Clinical Trials — Gainesville, Florida, United States (enrolling)
Clinical Neuroscience Solutions, Inc. — Jacksonville, Florida, United States (enrolling)
Avantis Clinical Research LLC — Miami, Florida, United States (enrolling)
Hope Research Network, LLC. — Miami, Florida, United States (enrolling)
Medical Research Group of Central Florida — Orange City, Florida, United States (enrolling)
Clinical Neuroscience Solutions, Inc. — Orlando, Florida, United States (enrolling)
APG Research LLC — Orlando, Florida, United States (enrolling)
D&H Tamarac Research Center — Tamarac, Florida, United States (enrolling)
Pediatric Neurology and Epilepsy Specialists — Winter Park, Florida, United States (enrolling)
Advanced Discovery Research LLC — Atlanta, Georgia, United States (enrolling)
Clinical Integrative Research Center of Atlanta — Atlanta, Georgia, United States (enrolling)
CenExcel iResearch, LLC — Decatur, Georgia, United States (enrolling)
CenExel iResearch, LLC. — Savannah, Georgia, United States (enrolling)
Qualmedica Research, LLC. — Evansville, Indiana, United States (enrolling)
Kentucky Pediatric/Adult Research — Bardstown, Kentucky, United States (enrolling)
Qualmedica Research, LLC. — Owensboro, Kentucky, United States (enrolling)
DelRicht Research (Touro Medical Center) — New Orleans, Louisiana, United States (enrolling)
DelRicht Research — Prairieville, Louisiana, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.